Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GNLX NASDAQ:PRTC NASDAQ:RAPP NASDAQ:RGNX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGNLXGenelux$3.95+8.2%$3.44$1.95▼$5.89$137.87M-0.33119,978 shs294,287 shsPRTCPureTech Health$15.80-3.1%$17.97$13.30▼$24.99$393.59M1.115,010 shs1,787 shsRAPPRapport Therapeutics$23.76+2.4%$16.09$6.43▼$42.27$867.19M0.731.37 million shs1.67 million shsRGNXREGENXBIO$9.20-3.1%$8.75$5.03▼$13.48$479.38M1.17541,778 shs294,794 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGNLXGenelux+8.22%+17.21%+23.44%+29.08%+51.92%PRTCPureTech Health-3.13%-3.28%-10.96%-19.43%-20.56%RAPPRapport Therapeutics+2.41%+65.46%+52.31%+112.33%+25.65%RGNXREGENXBIO-3.06%-5.25%+3.02%-0.76%-27.62%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGNLXGenelux$3.95+8.2%$3.44$1.95▼$5.89$137.87M-0.33119,978 shs294,287 shsPRTCPureTech Health$15.80-3.1%$17.97$13.30▼$24.99$393.59M1.115,010 shs1,787 shsRAPPRapport Therapeutics$23.76+2.4%$16.09$6.43▼$42.27$867.19M0.731.37 million shs1.67 million shsRGNXREGENXBIO$9.20-3.1%$8.75$5.03▼$13.48$479.38M1.17541,778 shs294,794 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGNLXGenelux+8.22%+17.21%+23.44%+29.08%+51.92%PRTCPureTech Health-3.13%-3.28%-10.96%-19.43%-20.56%RAPPRapport Therapeutics+2.41%+65.46%+52.31%+112.33%+25.65%RGNXREGENXBIO-3.06%-5.25%+3.02%-0.76%-27.62%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGNLXGenelux 3.00Buy$20.33414.77% UpsidePRTCPureTech Health 0.00N/AN/AN/ARAPPRapport Therapeutics 3.00Buy$31.0030.47% UpsideRGNXREGENXBIO 2.83Moderate Buy$28.38208.42% UpsideCurrent Analyst Ratings BreakdownLatest GNLX, RAPP, RGNX, and PRTC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/8/2025RAPPRapport TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$31.00 ➝ $34.009/8/2025RGNXREGENXBIOChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$52.009/8/2025RGNXREGENXBIOHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$34.008/19/2025RGNXREGENXBIOHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$34.008/8/2025RGNXREGENXBIORoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$21.00 ➝ $17.008/8/2025RGNXREGENXBIOBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$50.00 ➝ $37.008/8/2025RGNXREGENXBIOChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$52.008/6/2025RAPPRapport TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$31.007/23/2025GNLXGeneluxHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy7/8/2025RAPPRapport TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$28.00(Data available from 9/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGNLXGenelux$10K14,919.15N/AN/A$0.76 per share5.20PRTCPureTech Health$4.83M78.93$2.31 per share6.84$17.04 per share0.93RAPPRapport TherapeuticsN/AN/AN/AN/A$8.35 per shareN/ARGNXREGENXBIO$83.33M5.58N/AN/A$5.24 per share1.76Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGNLXGenelux-$29.87M-$0.86N/AN/AN/AN/A-107.47%-83.14%11/13/2025 (Estimated)PRTCPureTech Health$27.78MN/A0.00N/AN/AN/AN/AN/AN/ARAPPRapport Therapeutics-$78.31M-$2.50N/AN/AN/AN/A-29.99%-28.64%11/6/2025 (Estimated)RGNXREGENXBIO-$227.10M-$3.44N/AN/AN/A-112.70%-66.95%-34.14%11/5/2025 (Estimated)Latest GNLX, RAPP, RGNX, and PRTC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025GNLXGenelux-$0.22-$0.20+$0.02-$0.20N/AN/A8/7/2025Q2 2025RAPPRapport Therapeutics-$0.87-$0.75+$0.12-$0.75N/AN/A8/7/2025Q2 2025RGNXREGENXBIO-$1.13-$1.38-$0.25-$1.38$40.87 million$21.36 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGNLXGeneluxN/AN/AN/AN/AN/APRTCPureTech HealthN/AN/AN/AN/AN/ARAPPRapport TherapeuticsN/AN/AN/AN/AN/ARGNXREGENXBION/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGNLXGeneluxN/A4.184.18PRTCPureTech HealthN/A8.499.33RAPPRapport TherapeuticsN/A22.7522.75RGNXREGENXBION/A3.133.13Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGNLXGenelux37.33%PRTCPureTech Health0.04%RAPPRapport TherapeuticsN/ARGNXREGENXBIO88.08%Insider OwnershipCompanyInsider OwnershipGNLXGenelux8.80%PRTCPureTech Health5.30%RAPPRapport Therapeutics13.57%RGNXREGENXBIO12.79%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGNLXGenelux1037.77 million34.45 millionNot OptionablePRTCPureTech Health10024.13 million22.85 millionNot OptionableRAPPRapport TherapeuticsN/A36.50 million31.55 millionN/ARGNXREGENXBIO37050.51 million44.05 millionOptionableGNLX, RAPP, RGNX, and PRTC HeadlinesRecent News About These CompaniesCurran Simpson Sells 7,734 Shares of REGENXBIO (NASDAQ:RGNX) StockSeptember 13 at 7:12 AM | insidertrades.comREGENXBIO Inc. (NASDAQ:RGNX) Given Consensus Rating of "Moderate Buy" by BrokeragesSeptember 13 at 2:27 AM | americanbankingnews.com405,281 Shares in REGENXBIO Inc. $RGNX Bought by Exome Asset Management LLCSeptember 11 at 6:17 AM | marketbeat.comREGENXBIO's (RGNX) Buy Rating Reaffirmed at HC WainwrightSeptember 10 at 8:51 AM | marketbeat.comREGENXBIO's (RGNX) Buy Rating Reaffirmed at Chardan CapitalSeptember 10 at 8:29 AM | marketbeat.comREGENXBIO (NASDAQ:RGNX) Earns Buy Rating from HC WainwrightSeptember 10 at 2:01 AM | americanbankingnews.comChardan Capital Reaffirms Buy Rating for REGENXBIO (NASDAQ:RGNX)September 10 at 2:01 AM | americanbankingnews.comA Glimpse Into The Expert Outlook On Regenxbio Through 6 AnalystsSeptember 9, 2025 | benzinga.comRegenxbio: Poised For Breakthrough With RGX-121 Gene Therapy In Hunter SyndromeSeptember 9, 2025 | seekingalpha.comREGENXBIO Inc. (RGNX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeptember 8, 2025 | seekingalpha.com50,969 Shares in REGENXBIO Inc. $RGNX Purchased by Ieq Capital LLCSeptember 8, 2025 | marketbeat.comInvesco Ltd. Purchases 27,341 Shares of REGENXBIO Inc. $RGNXSeptember 7, 2025 | marketbeat.comREGENXBIO reports positive data from Hunter syndromeSeptember 6, 2025 | msn.comRegenxbio reports ‘positive’ results from Phase I/II/III CAMPSIITE trialSeptember 6, 2025 | msn.comRegenxbio: Remains A "Buy Rating" Despite BLA Review Delay Of RGX-121 For Hunter SyndromeSeptember 6, 2025 | seekingalpha.comREGENXBIO Inc. $RGNX Shares Acquired by PDT Partners LLCSeptember 6, 2025 | marketbeat.comREGENXBIO Presents Positive Twelve-Month Pivotal Data from Phase I/II/III CAMPSIITE® Trial of RGX-121 for Treatment of MPS IISeptember 5, 2025 | prnewswire.comTrexquant Investment LP Purchases 308,516 Shares of REGENXBIO Inc. $RGNXSeptember 5, 2025 | marketbeat.comADAR1 Capital Management LLC Purchases 162,423 Shares of REGENXBIO Inc. $RGNXSeptember 4, 2025 | marketbeat.comHsbc Holdings PLC Sells 29,002 Shares of REGENXBIO Inc. $RGNXSeptember 4, 2025 | marketbeat.comNuveen LLC Makes New Investment in REGENXBIO Inc. $RGNXSeptember 4, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGNLX, RAPP, RGNX, and PRTC Company DescriptionsGenelux NASDAQ:GNLX$3.95 +0.30 (+8.22%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$3.95 0.00 (0.00%) As of 09/12/2025 05:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.PureTech Health NASDAQ:PRTC$15.60 -0.71 (-4.35%) As of 09/12/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.Rapport Therapeutics NASDAQ:RAPP$23.76 +0.56 (+2.41%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$23.69 -0.07 (-0.29%) As of 09/12/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rapport Therapeutics Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON.REGENXBIO NASDAQ:RGNX$9.20 -0.29 (-3.06%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$9.34 +0.14 (+1.47%) As of 09/12/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Tesla's U.S. Market Is At An 8-Year Low... How Bad Could It Get? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
